Boundless Bio, Inc. (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, has announced the pricing of its initial public offering of 6,250,000 shares of its common stock at an initial public offering price of US$16.00 per share. All of the shares are being offered by Boundless Bio. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be US$100.0 million. Boundless Bio’s common stock is expected to begin trading on the Nasdaq Global Select Market on March 28, 2024, under the ticker symbol “BOLD.” The offering is expected to close on April 2, 2024, subject to the satisfaction of customary closing conditions. In addition, Boundless Bio has granted the underwriters a 30-day option to purchase up to an additional 937,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions. Latham & Watkins LLP is advising Boundless Bio on the offering, with a corporate team led by San Diego partners Matt Bush and Cheston Larson, with associates Nadia Patino, Sterling Swift, and Arielle Schechtman. Advice was also provided on benefits matters by San Diego partner Holly Bauer, with associate Julie Voorhes; on FDA regulatory matters by Bay Area partner Betty Pang and Washington, D.C. counsel Chad Jennings, with San Diego associate Kiera Murphy; and on IP matters by San Diego counsel Darryl Steensma, with associates Robert Yeh and Kristina Funahashi.~~